Recursion

YouTube video by Recursion One Thing That Makes Me Excited to Come to Work at Recursion

What gets you excited?

In this video, Communications and Culture Fellow Katherine Matsumoto asks Recursionauts to share the “one thing” that most excites them about their work. #OneThing #culture

www.youtube.com/shorts/zQDQq...

Today, cofounder & CEO Chris Gibson spoke on the Main Stage at #GITEX to discuss how the convergence of AI, data, & DNA is fundamentally changing the way we discover medicines. As he wrote: “This is more than just a shift in technology — it’s a re-architecting of the scientific process itself."

🎫 Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan, PhD will join leading experts from healthcare, technology, and public policy for Google Cloud’s Cancer AI Symposium on Oct. 30 at Google NYC, exploring how #AI is currently transforming #cancer care – and what’s to come. 🧪

Inside the AI transformation of drug discovery.
On Oct. 15 on the Main Stage of GITEX Global at the Dubai World Trade Center, Recursion cofounder & CEO Chris Gibson will give a keynote on "AI, Data & DNA: TechBio’s Disruption of Drug Discovery." 👉 visit.gitex.com
#GITEXGlobal #GITEX2025 #TechBio

🎙️ Subscribe to TechBio Talks now on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...

Announcing TechBio Talks Episode 2: A deep dive into phenomics, open science and virtual cells.

Host Chris Gibson talks to the Broad Institute's Anne Carpenter, a pioneer in image-based profiling, who played a key role in Recursion’s origin story. 🧵

TechBio Talks Episode 1: MIT's Regina Barzilay with Host Najat Khan Spotify video

👇 Check out TechBio Talks on:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...
▪️ Apple: podcasts.apple.com/us/podcast/t...
or wherever you get your podcasts!

YouTube video by Recursion Using Machine Learning to Predict Patient Response to Treatment

In a clip from our podcast TechBio Talks, MIT's Regina Barzilay tells host Najat Khan how we can leverage machine learning to better predict how a patient will respond to treatments, to improve his or her condition for the “longest time with minimal side effects.” www.youtube.com/shorts/uSEM1... 🧵

Careers at Recursion: Join Our Mission | Recursion Embark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!

Driving this industry-defining innovation takes bold, bilingual thinkers who collaborate across disciplines, and push back against the status quo.

If this sounds like your kind of mission, we're hiring. www.recursion.com/careers

👉See the list: www.fastcompany.com/best-workpla...

We♥️our innovators.

Recursion was recognized as one of the “Best Workplaces for Innovators” by @fastcompany.com.

At Recursion, we're building a new kind of drug discovery & development platform from the ground up – relentlessly working toward a better way to bring new medicines to patients. 🧵

Maintaining our sense of urgency, because patients are waiting.

In a clip from the latest installment in our internal #RXU series – Chief R&D Officer and Chief Commercial Officer Najat Khan talks about the importance of urgency. #TechBio

A recent story in @reuters.com looks at momentum happening in #AI drug discovery, noting that AI adoption across the #pharma industry will lead to “faster and cheaper results” including through reduction in animal testing, a recent push from the #FDA. More: www.reuters.com/business/hea...

“We’re focused on going places that we don’t think other people can.” On 9/8, Chris Gibson & Najat Khan presented at the Morgan Stanley Global Healthcare Conference, addressing macro concerns, platform evolution & what we anticipate from partnership milestones
👉 event.webcasts.com/viewer/event...

A new feature in @financialtimes.com looks at what’s needed for #AI drug discovery to begin delivering on its promises and how the latest #ML breakthroughs paired with over a decade of fit-for-purpose data generation has positioned us for that moment.
👉 www.ft.com/content/9a8a...

🌄 The peak is now the basecamp.

A new feature in @pharmaphorum.bsky.social looks at how Recursion has built the necessary foundation & is now accelerating into a new era of AI-led drug discovery, focused on delivering transformative, first-in-class medicines. pharmaphorum.com/deep-dive/ai...

Read Occam's interview with AIDD leader Najat Khan, PhD. | Occam Global Read Occam's interview with AIDD leader Najat Khan, PhD.

In an interview with Occam, Recursion Chief R&D Officer and Chief Commercial Officer Najat Khan outlines the strategy for building a #TechBio company that’s positioned to win.

👉 Read more: www.occam-global.com/blogs/an-int...

🎉 Daniel Cohen, President of Valence Labs (@valenceai.bsky.social),
Recursion’s AI research engine, has been named a “Rising Leader” by Citeline. #TechBio #AI #ML #research #virtualcell

👉Read more: insights.citeline.com/in-vivo/lead...

📣 The inaugural episode of TechBio Talks is now live!
Host Najat Khan sits down w/ MIT Distinguished Professor Regina Barzilay for a fascinating conversation about the new AI technologies transforming healthcare.

▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: youtube.com/playlist?lis...

🔹 Join us in September as Recursion executives present at two upcoming investor conferences:

▪️ Sept. 3: Citi 2025 BioPharma Back to School Conference

▪️ Sept. 8: Morgan Stanley 23rd Annual Global Healthcare Conference

👉 Learn more and tune in here: ir.recursion.com.

#investor #IR #IRconference

🎙️ Introducing #TechBio Talks – a new podcast hosted by Chris Gibson & Najat Khan offering candid conversations with the scientists, founders, & investors on the frontlines of #AI drug discovery. Subscribe now:
▪️ Spotify: open.spotify.com/show/2bjoBPs...
▪️ YouTube: www.youtube.com/playlist?lis...

🔹 Delivering breakthroughs, at scale. Last week, Erik Douglas, VP of Product, joined some of the biggest names in tech – including Fei-Fei Li and Geoffrey Hinton – at the #Ai4 conference in Vegas where he provided insights into our AI-driven industrialization of drug discovery and development.

How Open Data Is Fueling the AI Drug Discovery Era - Future Medicine AI Big pharma is unlocking decades of secret data vaults for the first time, fueling an AI revolution that's compressing 50 years of drug discovery into mere months - and the cure for tomorrow's diseases...

🚀 Expanding access to data to accelerate #AI drug discovery.
A new article from @britabelli.bsky.social in Future Medicine AI looks at the critical role open datasets play in driving discoveries & initiatives underway to enable more access. www.fmai-hub.com/how-open-dat... #TechBio #drugdiscovery

An article in BioPharmaTrend highlighted our recent earnings report, including “progress on internal assets REC-1245 (RBM39 degrader) and REC-617 (CDK7 inhibitor), alongside a $7 million milestone payment from Sanofi for a partnered immunology program.” www.biopharmatrend.com/news/recursi...

YouTube video by Recursion Using Data & AI to Deliver a New Cancer Drug to Clinic Twice as Fast as Industry Average

In a new series called "Explain the Impact," Chase Neumann, Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify biomarkers that can better guide patient selection and improve outcomes. www.youtube.com/shorts/33ltb...

💡 “It’s not a taller ladder, it’s an elevator.”

In this video, Lina Nilsson, PhD, Chief Platform Officer, shares what we mean by industrialization at Recursion. The video is part of our internal RXU learning platform which provides deep dives into our mindset, mission, and value drivers. #TechBio

Anne Carpenter spoke at @mit.edu about the importance of #biology imaging in the age of #AI. Using phenotypic maps, she says, Recursion has “identified thousands of screenable image phenotypes & hundreds of potential therapeutics & launched multiple clinical trials.” www.youtube.com/watch?v=kP-G...

🚀 A new article from CURE looks at how open-source datasets & tools like Boltz-2 are “unlocking powerful capabilities once limited to Big Pharma,” allowing startups & researchers to “dramatically accelerate & de-risk R&D involved in discovering new medicines.” wewillcure.com/insights/the... #techbio

Using AI and Automation to Improve Outcomes in Infectious Diseases

In a new paper in @acs.org Infectious Diseases, Recursion scientists look at how #AI & automation are helping to tackle ongoing challenges in global public health by:
▪️ generating hypotheses
▪️ overcoming data scarcity
▪️ streamlining clinical trials

Read more: www.recursion.com/news/using-a...

At the AI x BIO Summit, hosted by Decoding Bio & NYSE, Recursion Chief R&D and Chief Commercial Officer Najat Khan spoke w/ @biotechtv.bsky.social
about how we’re addressing the high failure rate in drug discovery using data and AI.
👉 full conversation here: biotechtv.com/post/recursi... #TechBio

Join our (L)earnings Call on Tuesday, August 5.
Today Recursion announced that we will provide business updates and report our Q2 2025 financial results on Tues., Aug. 5, 2025 at 8am ET / 6am MT / 1pm BST.

👉 Submit questions: forms.gle/ciFX2KbLfkAv...

👉 Read more: ir.recursion.com/news-release...